Status:
RECRUITING
CEUS Evaluation of Hydrocephalus in Neonates and Infants
Lead Sponsor:
Children's Hospital of Philadelphia
Conditions:
Hydrocephalus in Infants
Hydrocephalus Acquired
Eligibility:
All Genders
1-18 years
Phase:
PHASE2
Brief Summary
Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion...
Detailed Description
Contrast-enhanced ultrasound (CEUS) is a clinically used imaging technique that uses gas-filled microbubbles to enhance the visualization of blood vessels. Ultrasound contrast agents have been approve...
Eligibility Criteria
Inclusion Criteria:
- Males and females younger than 1.5 years old with diagnosed and/or suspected hydrocephalus.
- Post menstrual age of 26 weeks or older.
- Inpatients at the Children's Hospital of Philadelphia.
- Parental/Legally authorized representative permission.
Exclusion Criteria:
- Medical history of Lumason hypersensitivity.
- Hemodynamic instability as defined by rapid escalation of cardiopulmonary support in the past 12-24 hours, as defined by the clinical care team.
- Respiratory instability as defined by rapid escalation of respiratory support in the past 12-24 hours (Increased fraction of inspired oxygen (FiO2) requirement and/or nitric oxide).
Key Trial Info
Start Date :
March 31 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06693752
Start Date
March 31 2026
End Date
August 1 2027
Last Update
February 20 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104